Cooperative Agreement U01HL083075

The National Heart, Lung, and Blood Institute (NHLBI) awarded Yale University a $764,853 Project Grant on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the CALM-OSA study through May 31, 2030. This research initiative will investigate the role of arousal threshold (ARTH)—an individual's propensity to awaken from respiratory stimuli—as a key determinant of treatment adherence and clinical outcomes in obstructive sleep apnea (OSA) patients receiving...

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $1.34 million Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award, effective September 1, 2025, through August 31, 2030, funds a five-year, three-site randomized controlled trial evaluating a structured, parent-mediated behavioral intervention for insomnia in young children...

Advancing Craniosynostosis Treatment (ACT) Rare Diseases Consortium The National Institute of Dental and Craniofacial Research (NIDCR) awarded The Children's Hospital of Philadelphia a Cooperative Agreement for $800,000 on August 19, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to establish and operate the Advancing Craniosynostosis Treatment (ACT) Rare Diseases Consortium through May 31, 2030. ACT is a multi-site, patient-centric translational and clinical research...

Federal Project Grant Award Summary The Medical University of South Carolina received a $210,013 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion by August 31, 2029. The grant funds a pilot randomized controlled trial (RCT) testing the REPOSE (Reach for Equity in Pediatric Obstructive Sleep Evaluation) Navigation Intervention, a multilevel, theory-based patient...

Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded The University of Texas Health Science Center at San Antonio $449,861 under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct a 24-month clinical observational feasibility study examining dental practitioners' oral appliance therapy (OAT) titration methods for obstructive sleep apnea (OSA) and their associated patient outcomes. Initiated on June 17, 2025, the...

Federal Cooperative Agreement Summary The National Heart, Lung, and Blood Institute awarded a $2.63 million Cooperative Agreement to The Johns Hopkins University effective September 15, 2025, through August 31, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds the ASTRO (Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis) trial, a multicenter, prospective, randomized, double-blinded, placebo-controlled clinical study designed to evaluate the...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $398,822 to the University of Texas Health Science Center at San Antonio on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multicenter, randomized controlled pilot trial evaluating nebulized tranexamic acid (TXA) for pediatric post-tonsillectomy hemorrhage (PTH). The study, titled "Tranexamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage...

Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Arizona a $172,085 Project Grant on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct translational research on light-based intervention strategies for improving sleep and circadian health in early childhood. The primary deliverable is a five-week feasibility and preliminary efficacy study involving children ages 5.0–6.9 years with parent-reported sleep onset...

ADAPT Trial Cooperative Agreement Summary The National Eye Institute (NEI) awarded The Regents of the University of California, San Francisco a cooperative agreement valued at $1,662,447 (awarded May 1, 2026, with completion anticipated April 30, 2030) under the Vision Research program (CFDA 93.867) to conduct the Adalimumab Dose Adjustment for Pediatric Uveitis Treatment (ADAPT) Trial. This multicenter, randomized controlled trial will generate evidence-based dosing guidelines for adalimumab in...

This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research examining asthma control trajectories in pediatric and adolescent populations with emphasis on sleep's influence. Awarded to Virginia Commonwealth University on March 12, 2026, with $148,614 in obligated funds and a completion date of September 29, 2028, the project leverages existing data from the RVA BREATHES study comprising...